Tumor Necrosis Factor Alone Does Not Explain the Lethal Effect of Lipopolysaccharide

Archives of Surgery

Volumn 126, Issue 2, 1991, Pages 231-235

  Sánchez Cantú, Leopoldo ^a,b   Rode, Harold N ^a,c   Yun, Theodore J ^a   Christou, Nicolas V ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Federico Gómez   (United States)

^c Immunology Section Bureau of Biologics HWC ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; CONFERENCE PAPER; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS;

ANIMAL; ANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; LETHAL DOSE 50; LIPOPOLYSACCHARIDES; MALE; PSEUDOMONAS AERUGINOSA; RATS; RATS, INBRED STRAINS; SALMONELLA TYPHI; SHOCK, SEPTIC; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TUMOR NECROSIS FACTOR;

EID: 0026035263     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.1991.01410260121017     Document Type: Article

References (38)

1. Flick DA, Gifford GE. Pharmacokinetics of murine tumor necrosis factor. J Immunopharmacol. 1986;8:89-97.
2. Michie HR, Monogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
3. Beutler B, Milsark IW, Cerami AC. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;125:3972-3977.
4. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988;81:1925-1937.
5. Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 1986;320:584-588.
6. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
7. Natanson C, Eichenholtz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823-832.
8. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869-871.
9. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-664.
10. Kiener PA, Marek F, Rodgers G, Ling PF, Warr G, Desiderio J. Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 1988;141:870-874.
11. Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Nati Acad Sci USA. 1988;85:607-611.
12. Neilson IR, Neilson KA, Junis EJ, Rowe MI. Failure of tumor necrosis factor to produce hypotensive shock in the absence of endotoxin. Surgery. 1989;106:439-443.
13. Beeson PB. Tolerance to bacterial pyrogens, I: factors influencing its development. J Exp Med. 1947;86:29-44.
14. Greisman SE, Hornick RB. Endotoxin tolerance. In: Beers RF, Bassett EG, eds. The Role of Immunological Factors in Infectious, Allergic, and Autoimmune Processes. New York, NY: Raven Press; 1976:43-63.
15. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Nati Acad Sci USA. 1979;76:5939-5943.
16. Greisman SE, Woodward WE. Mechanisms of endotoxin tolerance, III: the refractory state during continuous intravenous infusions of endotoxin. J Exp Med. 1965;121:911-933.
17. Greisman SE, Young EJ, Carozza FA. Mechanisms of endotoxin tolerance, V: specificity of the early and late phase of pyrogenic tolerance. J Immunol. 1969;103:1223-1236.
18. Zaldivar NM, Scher I. Endotoxin lethality and tolerance in mice: analysis with the B-lymphocyte-defective CBA/N strain. Infect Immunol. 1979;24:127-131.
19. Flick DA, Gifford GE. Production of tumor necrosis factor in unprimed mice: mechanism of endotoxin-mediated tumor necrosis. Immunobiology. 1986;171:320-328.
20. Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol. 1987;45:348-355.
21. Sánchez-Cantú L, Rode HN, Christou NV. Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg. 1989;124:1432-1436.
22. Voller A, Bidwell DE, Bartlett A. The enzyme linked immunosorbent assay (ELISA). In: A Guide to Abstracts of Microplate Applications. Guernsey: Flonline Publications; 1979.
23. Armitage P, Berry G. Statistical Methods in Medical Research. Boston, Mass: Blackwell Scientific Publications Inc; 1987.
24. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
25. Gifford GE, Lohmann-Matthes ML. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharides. J Natl Cancer Inst. 1987;78:121.
26. Palladino MA, Patton JS, Figar IS, Shalby MR. Possible relationships between in vivo anti-tumour activity and toxicity of tumor necrosis factor-alpha. In: Bock G, Marsh J, eds. Tumor Necrosis Factor and Related Cytotoxins. Ciba Foundation Symposium 131. New York, NY: John Wiley & Sons Inc; 1987:21-38.
27. Gollan F, McDermott J. Total hypothermic blood exchange in acute endotoxin shock. Resuscitation. 1979;7:229-236.
28. Green S, Dobrojansky A, Chiasson MA, Carswell E, Schwartz MK, Old LJ. Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst. 1977;59:1519-1522.
29. Senterfitt VC, Shands JW. Salmonellosis in mice infected with Mycobacterium tuberculosis BCG, I: role of endotoxin in infection. J Bacteriol. 1968;96:287.
30. Joyce LD, Hau T, Hoffman R, Simmons RL, Lillehei RC. Evaluation of the mechanism of zymosan-induced resistance to experimental peritonitis. Surgery. 1978;83:717-725.
31. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med. 1989;169:2021-2027.
32. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 1989;143:2894-2899.
33. Desiderio JV, Kiener PA, Lin P-F, Warr GA. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha. Infect Immunol. 1989;57:1615-1617.
34. Clark IA, Hunt NH, Butcher GA, Cowden WB. Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Immunol. 1987;139:3493-3496.
35. Djeu J, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol. 1986;137:2980.
36. Urbaschek R, Urbaschek B. Tumor necrosis factor and interleukin 1 as mediators of endotoxin-induced beneficial effects. Rev Infect Dis. 1987;9: 607-615.
37. Old LJ. Tumor necrosis factor (TNF). Science. 1985;230:630-632.
38. Zuckerman SH, Bendele AM. Regulation of serum tumor necrosis factor in glucocorticoid-sensitive and -resistant rodent endotoxin shock models. Infect Immunol. 1989;57:3009-3013.